Practical therapeutics. Psychotropic drugs.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001463:Barbiturates / Q000627:therapeutic use; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000188:drug therapy; D001569:Benzodiazepines / Q000627:therapeutic use; D002090:Butyrophenones / Q000009:adverse effects / Q000627:therapeutic use; D002746:Chlorpromazine / Q000627:therapeutic use; D004347:Drug Interactions; D006801:Humans; D008094:Lithium / Q000627:therapeutic use; D001523:Mental Disorders / Q000188:drug therapy; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D011409:Propylene Glycols / Q000627:therapeutic use; D011596:Psychomotor Disorders / Q000139:chemically induced; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D013892:Thioxanthenes / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000928:Antidepressive Agents; D000929:Antidepressive Agents, Tricyclic; D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D001463:Barbiturates; D002090:Butyrophenones; D008996:Monoamine Oxidase Inhibitors; D011409:Propylene Glycols; D011619:Psychotropic Drugs; D013892:Thioxanthenes; D001569:Benzodiazepines; D008094:Lithium; D002746:Chlorpromazine